Kailera Therapeutics is trading 7.75% down at $10.00 in pre-market on October 6, with no new company announcement or other clear catalyst identified for the decline. - Latest company updates were October 1 clinical data presented at EASD and completion of enrollment in the KaiNETIC Phase 3 program; these are prior news, not a confirmed explanation for this morning’s decline. - Broader indexes were higher, so the supplied market context does not explain the move.